Leerink Partners analyst Andrew Berens has maintained their bullish stance on CELC stock, giving a Buy rating on July 31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Buy rating due to a combination of factors related to Celcuity’s recent clinical trial results. The VIKTORIA-1 trial data for gedatolisib in second-line HR+ HER2- breast cancer patients showed impressive hazard ratios, indicating a significant potential benefit in treatment outcomes. The expert consulted in the analysis highlighted the strong performance of the gedatolisib combinations compared to the control, despite the control arm possibly underperforming.
Additionally, the safety profile of the treatment was noted to be better than previous studies, with lower rates of adverse effects such as hyperglycemia and stomatitis. These positive clinical outcomes, combined with the potential for gedatolisib to become a key player in the breast cancer treatment landscape, underpin Berens’s optimistic outlook and his Buy recommendation for Celcuity’s stock.
According to TipRanks, Berens is a 2-star analyst with an average return of 0.6% and a 42.18% success rate. Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Incyte, and Celcuity.